ChemCodes, a developer of chemical synthesis technology for the discovery and development of new medicinal compounds and materials, recently received $7.8 million in Series B funding. The company, which was built on technology licensed from Glaxo Wellcome, has appointed Robert Bell as interim chief executive officer. Bell is a former vice president in charge of research at Glaxo. Bell, who also is the founder of Sphinx Pharmaceuticals, is a part-time venture partner at Intersouth Partners of Durham. Intersouth led the new investment in ChemCodes, which also received financing from Noro-Moseley of Atlanta. www.chemcodes.com
CED News
« Gentris Announces Pharmacogenomics Collaboration with MDS Pharma Services | Main | A. M. Pappas Names Kenneth Lee as New President »